• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Metsera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    7/28/25 4:15:34 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email
    8-K
    false000204080700020408072025-07-282025-07-28

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 28, 2025

     

     

    METSERA, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-42489

    92-0931552

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    3 World Trade Center

    175 Greenwich Street

     

    New York, New York

     

    10007

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 212 784-6595

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.00001 per share

     

    MTSR

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On July 28, 2025, Metsera, Inc. announced financial results for the three and six months ended June 30, 2025, as well as a business update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

    The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

     

     

    Exhibit No.

     

    Description

     

     

    99.1*

     

    Press Release, dated July 28, 2025.

     

     

    104

     

    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

    *

    Furnished herewith.

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    METSERA, INC.

     

     

     

     

    Date:

    July 28, 2025

    By:

    /s/ Matthew Lang

     

     

     

    Matthew Lang
    Chief Legal Officer and Secretary

     


    Get the next $MTSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    9/30/2025$54.00Overweight → Equal Weight
    Wells Fargo
    9/9/2025$77.00Outperform
    Leerink Partners
    6/20/2025$65.00Overweight
    Wells Fargo
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Metsera downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Metsera from Overweight to Equal Weight and set a new price target of $54.00

    9/30/25 8:33:25 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Metsera with a new price target

    Leerink Partners initiated coverage of Metsera with a rating of Outperform and set a new price target of $77.00

    9/9/25 7:59:28 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Metsera with a new price target

    Wells Fargo initiated coverage of Metsera with a rating of Overweight and set a new price target of $65.00

    6/20/25 7:54:18 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer Completes Acquisition of Metsera

    Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer's Internal Medicine portfolio Positions Pfizer to lead in one of the most dynamic and high-growth therapeutic areas Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. "This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resou

    11/13/25 11:26:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

    Revised transaction values Metsera at up to $86.25 per shareMetsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with PfizerTransaction creates real, certain and immediate value for Metsera's stockholders and ensures Metsera's important drug candidates can emerge as key competitors available to all patientsNEW YORK, Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value

    11/7/25 9:32:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Issues Statement in Response to Litigation Ruling

    NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer: "Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restraining order to block Metsera's Board of Directors from acting in the best interests of shareholders. Separately, Pfizer has reiterated it will continue to spuriously litigate. As we have previously noted, Pfizer's litigation arguments are nonsense. Metsera's Board of Directors will continue to stand firm on behalf of shareholders and patients." Disclosure Notice This rel

    11/5/25 7:17:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:15:35 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:04:05 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:01:33 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    SEC Filings

    View All

    SEC Form 15-12G filed by Metsera Inc.

    15-12G - Metsera, Inc. (0002040807) (Filer)

    11/24/25 8:36:08 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

    SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

    11/17/25 1:59:38 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Metsera Inc.

    SCHEDULE 13D/A - Metsera, Inc. (0002040807) (Subject)

    11/14/25 6:22:29 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    See Remark 1 Fmr Llc disposed of 2,233,460 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/17/25 1:51:07 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Arch Venture Partners Xii, Llc returned 26,816,808 shares to the company (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/14/25 6:34:16 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER Lang Matthew returned 12,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/13/25 9:20:03 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Financials

    Live finance-specific insights

    View All

    Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

    Revised transaction values Metsera at up to $86.25 per shareMetsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with PfizerTransaction creates real, certain and immediate value for Metsera's stockholders and ensures Metsera's important drug candidates can emerge as key competitors available to all patientsNEW YORK, Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value

    11/7/25 9:32:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    /C O R R E C T I O N -- Metsera, Inc./

    In the news release, Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior", issued 04-Nov-2025 by Metsera, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should begin "Shortly thereafter,..." rather than "On the same day,...", and the third paragraph, first sentence, should read "...representing up to $24.00 per share in cash (up from $21.25)..." rather than "...representing up to $24.00 per share in cash (up from $22.50)..." as originally issued inadvertently. The complete, corrected release follows: Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Ame

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

    Novo Nordisk Amended Proposal Values Metsera at up to $86.20 per Share, a Total of Approximately $10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $70.00 per Share, a Total of Approximately $8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nord

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care